Evidence map›Paper›PMID 42889352›Full record

ReviewFrontiers in immunology2026

CD8

Hua Fu, Jing Yang, Miao Zhang

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hua FuThe Second Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Jing YangThe Second Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Miao ZhangThe Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) has traditionally been interpreted through amyloid, tau, and innate immune frameworks, with the complement cascade long regarded as the principal driver of aberrant synaptic pruning. Synaptic loss is increasingly recognized as one of the strongest correlates of cognitive decline. This review examines an emerging CD8

Indexed as

Alzheimer DiseaseCD8-Positive T-LymphocytesSynapsesAnimalsBrainHumansMicrogliaAlzheimer’s diseaseCD8+ T cellscomplement cascadegranzyme KMHC class Imicroglianeuroimmunologysynaptic integrity

Identifiers

PMID42889352
PMCPMC13669829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.